The unit develops, evaluates, and clinically applies pharmacologic treatments for cancer, combining preclinical studies, translational research, early-phase clinical trials, pharmacokinetic, pharmacodynamic and pharmacogenetic investigations, therapeutic drug monitoring, and adverse drug reaction analysis. We act as a multidisciplinary hub bridging bench and bedside, optimizing the therapeutic index of cancer drugs through rigorous pharmacological science.
Research units
/
Cancer Pharmacology Unit
Cancer Pharmacology Unit
6 researchers
Research areas
Metronomic chemotherapy
Chronic low-dose cytotoxic regimens for frail and elderly patients.
New targets and drug development
Tyrosine kinase inhibitors and MC4R antagonists in solid tumors.
Pharmacogenetics of antineoplastics
SNP interaction profiles for personalizing antiangiogenic therapy.
Pharmacodynamic biomarkers
Angiogenesis and immune biomarkers of activity and toxicity.
Pharmacokinetics and TDM
Therapeutic drug monitoring in collaboration with AOUP.
Pharmacology in cancer neuroscience
Antiepileptic drug repositioning and brain tumor pharmacology.
Recent publications
Team
Prof. Guido Bocci
MD PhD · Head of unit
Paola Orlandi
Biologist (MSc), PhD
Marta Banchi
PharmD
Arianna Bandini
PharmD
Costanza Tacchi
PharmD
Donghao Tang
MD
